Eli Lilly helps struggling Sangamo with $1.4B gene therapy deal  Fierce Biotech

Cell therapy biotech Neurona nabs $102M to push epilepsy candidate into phase 3  Fierce Biotech

Siemens AG to acquire lab R&D platform Dotmatics for $5.1B  Fierce Biotech

Roche shows most Alzheimer's patients below amyloid threshold after 28 weeks  Fierce Biotech

Boehringer commits $31M to ADC R&D via new Swiss facility for NBE Therapeutics  Fierce Biotech

Concentra swoops in to buy struggling Allakos, softening the blow of other denied buyout attempts  Fierce Biotech

Elon Musk expected to step down from DOGE leadership role: Politico  Fierce Biotech

'Patently illegal': NIH and HHS face new lawsuit over $1.1B in revoked research grants  Fierce Biotech

British biotech CellCentric expands to Boston with plans to grow into late-stage clinical development  Fierce Biotech

Princeton and Harvard join other Ivy League schools facing funding cuts, putting research at risk  Fierce Biotech

FDA’s chief medical officer Hilary Marston is out amid mass layoffs  Fierce Biotech

Sanofi taps Nurix for pipeline nourishment once again, picking up autoimmune degrader for $15M  Fierce Biotech

Atsena raises $150M for ocular gene therapies with Bain, Sofinnova in tow  Fierce Biotech

Patient suffers side effect in Cabaletta autoimmune CAR-T trial, but analysts unfazed  Fierce Biotech

Flagship-backed Sail Biomedicines lays off staff following review of organizational structure  Fierce Biotech

Federal judge blocks FDA's regulation of lab-developed tests  Fierce Biotech

Cerevance fails phase 2 trial in early, untreated Parkinson's  Fierce Biotech

After Eric Green's exit, new leader of NIH's genome research institute put on administrative leave: Stat  Fierce Biotech

Pfizer, Flagship tap Valo Health for autoimmune offshoot of multibillion-dollar collab  Fierce Biotech

A look inside biopharma’s Q1: 8 closures and 63 layoff waves  Fierce Biotech

Project Optimus: Transforming Dose Optimization in Oncology Drug Development  Fierce Biotech

Merck KGaA pays $85M to nab global rights for Abbisko's rare tumor drug after phase 3 win  Fierce Biotech

Carisma winds down operations, lays off 95% of remaining staff  Fierce Biotech

Lundbeck ends subcutaneous migraine cohort after futility review, pivots to IV formulation  Fierce Biotech

Cancer biotech Inspirna winding down as its odyssey in microRNA comes to an end  Fierce Biotech